Revive Therapeutics Ltd. (CSE:RVV)
Canada · Delayed Price · Currency is CAD 0.0250
0.00 (0.00%)
Aug 28, 2026, 2:29 PM EST
Revive Therapeutics Balance Sheet
Financials in millions CAD. Fiscal year is July - June.
Millions CAD. Fiscal year is Jul - Jun.
Assets
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Jun '25 Jun 30, 2025 | Jun '24 Jun 30, 2024 | Jun '23 Jun 30, 2023 | Jun '22 Jun 30, 2022 | Jun '21 Jun 30, 2021 |
Cash & Equivalents | 0.01 | 0.01 | 0.77 | 2.09 | 3.92 | 16.6 |
Cash & Short-Term Investments | 0.01 | 0.01 | 0.77 | 2.09 | 3.92 | 16.6 |
Cash Growth | -72.72% | -98.12% | -62.96% | -46.69% | -76.41% | 1020.48% |
Accounts Receivable | - | - | 0.01 | 0.14 | 0.11 | 0.09 |
Other Receivables | 0.07 | - | 0.01 | 0.02 | 0.08 | 0.03 |
Receivables | 0.07 | - | 0.02 | 0.16 | 0.19 | 0.13 |
Prepaid Expenses | 0.06 | 0.04 | 0.3 | 0.06 | 0.06 | 0.07 |
Restricted Cash | 0.01 | 0.01 | 0.05 | 0.05 | - | - |
Total Current Assets | 0.15 | 0.07 | 1.14 | 2.35 | 4.16 | 16.79 |
Property, Plant & Equipment | 0 | 0 | 0 | 0 | 0 | 0 |
Long-Term Investments | 0.13 | 0.14 | 0.12 | 0.16 | 0.25 | 0.25 |
Other Intangible Assets | - | - | 9.38 | 11.72 | 12.5 | 12.5 |
Long-Term Accounts Receivable | - | - | - | 0.01 | 0.15 | 0.26 |
Total Assets | 0.28 | 0.21 | 10.64 | 14.25 | 17.07 | 29.81 |
Liabilities
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Jun '25 Jun 30, 2025 | Jun '24 Jun 30, 2024 | Jun '23 Jun 30, 2023 | Jun '22 Jun 30, 2022 | Jun '21 Jun 30, 2021 |
Accounts Payable | 3.32 | 2.65 | 2.58 | 2.66 | 3.92 | 0.44 |
Accrued Expenses | 0.84 | 0.87 | 0.72 | 0.64 | 0.14 | 0.07 |
Current Portion of Leases | - | - | 0.03 | 0.13 | 0.11 | 0.09 |
Total Current Liabilities | 4.15 | 3.51 | 3.32 | 3.44 | 4.17 | 0.6 |
Long-Term Debt | 0.07 | 0.07 | - | 0.06 | 0.06 | 0.06 |
Long-Term Leases | - | - | - | 0.03 | 0.16 | 0.27 |
Other Long-Term Liabilities | 0.08 | 0.08 | 0.08 | 0.08 | 0.08 | 0.07 |
Total Liabilities | 4.31 | 3.66 | 3.4 | 3.6 | 4.46 | 1 |
Shareholders' Equity
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Jun '25 Jun 30, 2025 | Jun '24 Jun 30, 2024 | Jun '23 Jun 30, 2023 | Jun '22 Jun 30, 2022 | Jun '21 Jun 30, 2021 |
Common Stock | 47.86 | 47.7 | 47.5 | 45.98 | 43.11 | 42.43 |
Additional Paid-In Capital | 25.79 | 23.63 | 23.51 | 12.66 | 12.4 | 11.39 |
Retained Earnings | -78.22 | -77.2 | -66.19 | -60.57 | -54.25 | -36.44 |
Comprehensive Income & Other | 0.55 | 2.41 | 2.41 | 12.58 | 11.34 | 11.43 |
Shareholders' Equity | -4.02 | -3.46 | 7.23 | 10.65 | 12.6 | 28.81 |
Total Liabilities & Equity | 0.28 | 0.21 | 10.64 | 14.25 | 17.07 | 29.81 |
Additional Metrics
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Jun '25 Jun 30, 2025 | Jun '24 Jun 30, 2024 | Jun '23 Jun 30, 2023 | Jun '22 Jun 30, 2022 | Jun '21 Jun 30, 2021 |
Total Debt | 0.07 | 0.07 | 0.03 | 0.22 | 0.33 | 0.42 |
Net Cash (Debt) | -0.06 | -0.05 | 0.75 | 1.87 | 3.59 | 16.18 |
Net Cash Growth | - | - | -59.96% | -47.94% | -77.83% | 1493.48% |
Net Cash Per Share | -0.00 | -0.00 | 0.00 | 0.01 | 0.01 | 0.06 |
Filing Date Shares Outstanding | 435.68 | 432.32 | 418.56 | 357.65 | 321.13 | 317.96 |
Total Common Shares Outstanding | 435.68 | 425.21 | 418.56 | 357.65 | 321.42 | 317.96 |
Working Capital | -4.01 | -3.45 | -2.18 | -1.08 | -0 | 16.2 |
Book Value Per Share | -0.01 | -0.01 | 0.02 | 0.03 | 0.04 | 0.09 |
Tangible Book Value | -4.02 | -3.46 | -2.15 | -1.07 | 0.1 | 16.31 |
Tangible Book Value Per Share | -0.01 | -0.01 | -0.01 | -0.00 | 0.00 | 0.05 |
Machinery | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 |